143
“`html
Layoffs Hit Recursion as Biotech Sector Faces Headwinds
Recent workforce reduction reflects broader challenges in biotech funding and market sentiment.
In a difficult decision, 20% of the team at Recursion was let go, according to a company statement.
The leadership at Recursion made the decision with a focus on the company’s mission, though the process was described as remarkably painful with heartbreaking human costs.
Recursion is not alone. Layoffs, pipeline cuts, and corporate restructurings are increasingly common due to macroeconomic challenges.Biotech stocks are struggling, capital is
